Objective to evaluate the efficacy of Xuebijing injection in treating 2019 novel coronavirus (2019-nCoV) : a prospective multicenter cohort study.

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ITMCTR

Registry ID

ITMCTR2000002938

Enrollment

Unknown

Registered

2020-01-27

Start date

2020-01-27

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

2019 novel coronavirus (2019-nCoV)

Interventions

Xuebijing group:Standard treatment+Xuebijing Injiection

non-Xuebijing group:Standard treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with 2019-nCoV confirmed by etiological examination; 2. Aged >=18 years old; 3. Pneumonia Severity Index(PSI) III-V or Oxygenation index<=300mmHg; 4. Required treatment in ICU; 5. Sign informed consent.

Exclusion criteria

Exclusion criteria: 1. XBJ treatment started before admission to ICU; 2. Treatment with another experimental drug for 2019-nCoV; 3. Opposition to data collection by patients or their legal representative.

Design outcomes

Primary

Measure	Time frame
pneumonia severity index (PSI);	—

Secondary

Measure	Time frame
duration of mechanical ventilation;Length of stay in ICU;28-day discharge rate;28-day prognosis;	—

Countries

China

Contacts

Public ContactNanshan Zhong / Yuanlin Song / Haibo Qiu / Bin Du / Yimin Li / Xiaoqing Liu

The First Affiliated Hospital of Guangzhou Medical University

ylsong70@163.com020-34294311

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026